Advertisement
Advertisement
MGX
Metagenomi Therapeutics, Inc. Common Stock
0.71
USDSponsored
-0.02
-2.93%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.72
+0.01
+1.07%
Metagenomi Therapeutics, Inc. Common Stock (MGX) Earnings
MGX Earnings Reports
Positive Surprise Ratio
MGX beat 7 of 11 last estimates.
64%
Next Report
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
$2.08M
/-$0.64
Implied change from Q2 26 (Revenue/ EPS)
+709.57%
/-12.33%
Implied change from Q3 25 (Revenue/ EPS)
-75.97%
/+16.36%
Metagenomi Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, MGX reported earnings of -0.73 USD per share (EPS) for Q2 26, missing the estimate of -0.57 USD, resulting in a -26.58% surprise. Revenue reached 257.00 thousand, compared to an expected 2.99 million, with a -91.40% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.64 USD, with revenue projected to reach 2.08 million USD, implying an decrease of -12.33% EPS, and increase of 709.57% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Teva Pharmaceutical Industries Limited
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.74
Actual
$0.86
Surprise
+15.50%
BridgeBio Pharma, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.59
Actual
-$0.42
Surprise
+28.90%
Supernus, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.49
Actual
$0.92
Surprise
+84.07%
Bausch Health Companies Inc
Report Date
Oct 28, 2026 For Q3 26
Estimate
$1.30
Actual
$1.77
Surprise
+35.50%
Amphastar Pharmaceuticals, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.87
Actual
$1.13
Surprise
+30.18%
FAQ
What were Metagenomi Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Metagenomi Therapeutics, Inc. Common Stock reported EPS of -$0.73, missing estimates by -26.58%, and revenue of $257.00K, -91.4% below expectations.
How did the market react to Metagenomi Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -1.63%, changed from $1.23 before the earnings release to $1.21 the day after.
When is Metagenomi Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 18, 2026.
What are the forecasts for Metagenomi Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Metagenomi Therapeutics, Inc. Common Stock is expected to report EPS of -$0.64 and revenue of $2.08M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.